The proposed cross-cancer TP53 prediction model offers a promising noninvasive tool for tumor molecular subtyping, with potential applications in personalized treatment planning, early risk stratification, and selection of targeted therapeutic strategies. The gene discussed is TP53; the disease is neoplasm.